This site is intended for health professionals only
Thursday 27 June 2019
Share |

Anti-depression drug approval sought

British pharmaceutical giant AstraZeneca is lobbying the US drugs regulator to approve a schizophrenia treatment for use among patients with depression and anxiety disorders.

The Food and Drug Administration (FDA) said it recognises that Seroquel XR does work against depression,  though there are concerns about its side effects, including the risk of sudden heart death.

Millions of people with schizophrenia and bipolar disorder already use the drug to help manage their condition, and AstraZeneca now wants the FDA to approve it as a treatment for depression and anxiety disorders.

A panel of outside experts is due to give the FDA its opinion about the consequences of exposing more patients to Seroquel's side effects, such as weight gain and nervous tics.

FDA drug reviewer Thomas Laughren said: "There remains a concern about longer-term risks with this drug, in particular risks related to metabolic changes.

He also cited a recent article in the New England Journal of Medicine that suggests antipsychotic drugs such as Seroquel can increase the risk of sudden cardiac death.

Aside from these safety concerns, the agency has already concluded that Seroquel is effective at controlling depression based on a number of company studies.

Copyright Press Association 2009


Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher